Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal Type 2 signalling? The MeDALL hypothesis

Allergy (Open access)

Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)

J Bousquet, JM Anto, M Wickman et al.

Abstract

Allergic diseases (asthma, rhinitis and atopic dermatitis) are complex. They are associated with allergen-specific IgE and non-allergic mechanisms that may coexist in the same patient. In addition, these diseases tend to cluster and patients present concomitant or consecutive diseases (multimorbidity). IgE sensitization should be considered as a quantitative trait. Important clinical and immunological differences exist between mono or polysensitized subjects.

Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol

Study protocol

Melina Makatsori^12*, Gianenrico Senna³, Constantinos Pitsios⁴, Ramon Lleonart⁵, Ludger Klimek⁶, Carlos Nunes⁷,Maia Rukhadze⁸, Barbara Rogala⁹, Radoslaw Gawlik⁹, Petr Panzner¹⁰, Oliver Pfaar¹¹⁶ and Moises Calderon¹²

Clinical and Translational Allergy 2015, 5:17  doi:10.1186/s13601-015-0060-0

Abstract

Background

Adherence to allergen immunotherapy is important for its effectiveness. There is currently limited data available on allergen immunotherapy adherence outside of clinical trials i.e. in real-life clinical practice. As part of a European Academy of Allergy and Clinical Immunology Immunotherapy Interest group initiative, we endeavoured to design a survey in order to prospectively evaluate adherence to subcutaneous and sublingual immunotherapy across different European countries.

Chronic vulvovaginal Candida hypersensitivity: An underrecognized and undertreated disorder by allergists

Allergy & Rhinology, Volume 6, Number 1, 2015, pp. e44-e49(6)

Bernstein, Jonathan A.; Seidu, Luqman

Abstract:

Vulvovaginal candidiasis infections are estimated to occur at least once during the lifetime of 75% of the female population. It has been proposed that some women with recurrent vulvovaginal candidiasis (RVVC) develop sensitization to Candida albicans and clinically improve in response to Candida immunotherapy.

Patients’ perspective of barriers and facilitators to taking long-term controller medication for asthma: a novel taxonomy

Research article

Sandra Peláez¹, Alexandrine J Lamontagne¹, Johanne Collin², Annie Gauthier¹, Roland M Grad³, Lucie Blais², Kim L Lavoie⁴, Simon L Bacon⁵, Pierre Ernst⁶⁷, Hélène Guay⁸, Martha L McKinney⁹ and Francine M Ducharme^1101179*

BMC Pulmonary Medicine 2015, 15:42  doi:10.1186/s12890-015-0044-9

Abstract (provisional)

Background Although asthma morbidity can be prevented through long-term controller medication, most patients with persistent asthma do not take their daily inhaled corticosteroid. The objective of this study was to gather patients’ insights into barriers and facilitators to taking long-term daily inhaled corticosteroids as basis for future knowledge translation interventions. 

Effectiveness of Montelukast on asthma control in infants: methodology of a French claims data study

Research article

Manon Belhassen^129*, Gérard de Pouvourville³, Laurent Laforest², Jacques Brouard⁴, Jacques de Blic⁵, Brigitte Fauroux⁶, Valérie Laigle¹, Céline Chanut-Vogel¹, Liliane Lamezec¹ and Eric Van Ganse²⁷⁸

BMC Pulmonary Medicine 2015, 15:51  doi:10.1186/s12890-015-0047-6

Background This pilot study, conducted on a 1/97th representative sample of French claims data, prepared a project to assess the effectiveness of Montelukast (MTL-4) as add-on therapy for asthma in infants (6–24 months) compared to inhaled corticosteroids (ICS), based on real-world data. Due to the very recent opening of French claims data for effectiveness research, and the complex structure of this data source, we first tested the feasibility of identifying infants with asthma and outcome criteria, and the ability to perform relevant comparisons. 

Practical recommendations for mixing allergy immunotherapy extracts

Allergy & Rhinology, Volume 6, Number 1, 2015, pp. e1-e7(7)

Daigle, Barbara J.; Rekkerth, Donna J.

Abstract:

Critical aspects of formulating allergy immunotherapy vaccines include the selection, total number, and proportions of each allergen component in therapeutic mixtures. The immunotherapy prescription, determined by a medical provider, details the dosing and schedule for treatment as well as the specific composition of the treatment vials.

Human platelets and their capacity of binding viruses: meaning and challenges?

Review

Adrien Chabert¹, Hind Hamzeh-Cognasse¹, Bruno Pozzetto¹², Fabrice Cognasse¹³, Mirta Schattner⁴, Ricardo M Gomez⁵ and Olivier Garraud^167*

BMC Immunology 2015, 16:26  doi:10.1186/s12865-015-0092-1

Abstract

Blood platelets are first aimed at ensuring primary hemostasis. Beyond this role, they have been acknowledged as having functions in the maintenance of the vascular arborescence and, more recently, as being also innate immune cells, devoted notably to the detection of danger signals, of which infectious ones. Platelets express pathogen recognition receptors that can sense bacterial and viral moieties.

The Allergic Rhinitis – Clinical Investigator Collaborative (AR-CIC): nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapies

Research

Anne K Ellis^12*, Mena Soliman¹, Lisa Steacy², Marie-Ève Boulay³, Louis-Philippe Boulet³, Paul K Keith⁴, Harissios Vliagoftis⁵, Susan Waserman⁴ and Helen Neighbour⁶

Allergy, Asthma & Clinical Immunology 2015, 11:16  doi:10.1186/s13223-015-0082-0

Abstract (provisional)

Background The Nasal Allergen Challenge (NAC) model allows the study of Allergic Rhinitis (AR) pathophysiology and the proof of concept of novel therapies. The Allergic Rhinitis – Clinical Investigator Collaborative (AR-CIC) aims to optimize the protocol, ensuring reliability and repeatability of symptoms to better evaluate the therapies under investigation.